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Little is known of the involvement of endocannabinoids and can-
nabinoid receptors in skeletal muscle cell differentiation. We re-
port that, due to changes in the expression of genes involved in its
metabolism, the levels of the endocannabinoid 2-arachidonoylgly-
cerol (2-AG) are decreased both during myotube formation in vitro
from murine C2C12 myoblasts and during mouse muscle growth in
vivo. The endocannabinoid, as well as the CB1 agonist arachido-
noyl-2-chloroethylamide, prevent myotube formation in a manner
antagonized by CB1 knockdown and by CB1 antagonists, which,
per se, instead stimulate differentiation. Importantly, 2-AG also
inhibits differentiation of primary human satellite cells. Muscle fas-
cicles from CB1 knockout embryos contain more muscle fibers, and
postnatal mice show muscle fibers of an increased diameter relative
to wild-type littermates. Inhibition of Kv7.4 channel activity, which
plays a permissive role in myogenesis and depends on phosphatidy-
linositol 4,5-bisphosphate (PIP2), underlies the effects of 2-AG. We
find that CB1 stimulation reduces both total and Kv7.4-bound PIP2
levels in C2C12 cells and inhibits Kv7.4 currents in transfected CHO
cells. We suggest that 2-AG is an endogenous repressor of myoblast
differentiation via CB1-mediated inhibition of Kv7.4 channels.
The endocannabinoid system (ECS) refers to a large group ofendogenous molecules including the two major arachidonate-
derived neuromodulatory mediators, anandamide (AEA) and
2-arachidonoylglycerol (2-AG), known as endocannabinoids (EC);
several enzymes involved in the metabolism of AEA (NAPE-PLD,
ABDH4, GDE1, PTPN22 for biosynthesis and FAAH for degra-
dation) and 2-AG (DAGLα and DAGLβ for biosynthesis and
MAGL, ABDH6, ABDH12, and FAAH for degradation); and
two G protein-coupled receptors known as cannabinoid receptor
of type-1 (CB1) and type-2 (CB2). AEA also activates the cation
permeant transient receptor potential vanilloid type-1 (TRPV1)
channels (1). In mammals, the ECS regulates a large number of
physiological processes; alterations in its activity are in fact re-
sponsible for the onset or progression of many types of disorders
affecting both the central and the peripheral nervous system as
well as other organs (2–5). So far, a few studies have reported that
CB1 receptor activity controls key skeletal muscle metabolic
processes such as insulin signaling, glucose uptake, and fatty acid
oxidation (6, 7). However, little, if anything at all, is known about
the expression profile and the functional role played by the ECS
during skeletal muscle development.
Skeletal myogenesis is a tightly regulated process that requires
coordinated changes in a large number of genes allowing pro-
liferating myoblasts to withdraw from the cell cycle and fuse to form
large multinucleated myotubes (8). Several classes of ion channels
play a pivotal role in the initiation of the differentiation process. For
example, the sequential activation of two distinct classes of K+
channels, the ether-a-go-go Kv10.1 and the inward-rectifier KIR2.1
(9, 10), is known to be one of the first molecular events that causes
myoblast hyperpolarization. This event, in turn, leads to the acti-
vation of voltage-dependent T-type Ca2+ channels, which increase
the [Ca2+]i necessary to initiate myoblast commitment to differen-
tiation into myotubes (11). More recently, members of the Kv7
(KCNQ) subfamily of voltage-activated K+ channels have been
found to be expressed in both myoblasts and myotubes (12,
13), and, in particular, it has been shown that Kv7.4 channel
expression plays a permissive role in skeletal myogenesis (14).
The Kv7 subfamily comprises five subunits (Kv7.1–Kv7.5), each
showing distinct tissue distribution and physiological properties.
Kv7 channel function is regulated by several classes of Gq/11-
coupled receptors including muscarinic (15), bradikynin (16),
serotonin (17), and somatostatin receptors (18). Stimulation of
these receptors leads to phospholipase C (PLC) activation and
subsequent hydrolysis of phosphatidylinositol 4,5-bisphosphate
(PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol
(DAG). Thus, considering that PIP2 is strictly required for Kv7
channels activity, Gq/11-coupled receptor stimulation represents
one of the most important cellular mechanisms through which
this subclass of K+ channels is kept under negative control (19).
Interestingly, the M current, which is underlied by Kv7 channels,
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can be also inhibited following CB1 receptor stimulation by AEA
at the postsynaptic level in hippocampal neurons (20) or by
stimulation of the Gq/11-coupled orphan receptor GPR55 (21).
In this study, we have endeavored to understand the role
played by the ECS in muscle development and its impact on Kv7
activity during myogenesis by using molecular biology, bio-
chemical, pharmacological, morphological, and electrophysio-
logical techniques. Our results indicate that the endocannabinoid
2-AG tonically inhibits differentiation of mouse and human
myoblasts via sequential activation of CB1 receptors, reduction
of PIP2 levels, and inhibition of Kv7 channel activity.
Results
Levels of AEA and 2-AG and mRNA Expression Profile of Genes
Related to Their Metabolism During C2C12 Cell Differentiation. To
gain information about the tone of the ECS and its potential
changes during in vitro myogenesis, we measured AEA and 2-AG
levels in C2C12 cells by liquid chromatography atmospheric pressure
chemical ionization mass spectrometry (LC-APCI-MS) in myoblasts
and after 3 and 7 d of their exposure to differentiation medium
(DM). We found that, during myotube formation, AEA levels
tended to decrease albeit not reaching statistical significance
(Fig. 1A), whereas 2-AG levels strongly declined already after 3 d
of myoblast exposure to DM and remained reduced up to at
least day 7 of the differentiation program (Fig. 1A). To understand
whether the changes in EC levels were due to changes in the
mRNA expression of EC metabolic enzymes, we determined by
quantitative PCR (qPCR) the mRNA expression profile for the
entire set of genes known to encode for enzymes involved in EC
synthesis (such as Napepld, Abdh4, Gde1, and Ptpn22 for AEA or
Dagla andDaglb for 2-AG) and degradation (such as Faah for AEA
or Magl, Abdh6/12, and Faah for 2-AG) (Table S1). Our analysis
revealed that during myotube formation the expression profile of
genes involved in AEA metabolism was not significantly changed,
except for Ptpn22 and Faah, the mRNA transcript levels of which
were slightly decreased in myotubes (Fig. 1B). In contrast, among
the genes related to 2-AG metabolism, the expression of Dagla
and Abhd12 was slightly reduced (by less than twofold), whereas
Magl expression was significantly up-regulated (by about twofold)
during C2C12 cell differentiation (Fig. 1B). Accordingly, Western
blot analysis revealed that, concomitant to increased myosin heavy
chain (MyHC) protein expression during C2C12 cell differentia-
tion, Dagla levels are not significantly changed, although a de-
creasing trend is observed at 72 h, whereas Magl levels increase
steadily over time (Fig. 1C).
Potential changes in AEA and 2-AG levels were then evalu-
ated in mouse muscle at different developmental stages. The
quadriceps femoris muscle was dissected from the leg of mouse
embryos or pups at embryonic day 18 (E18) or at postnatal days
4 and 14 (P4 and P14), and its purified lipid extract was sub-
sequently subjected to LC-APCI-MS analysis. As shown in Fig.
1D, endogenous levels of AEA decreased by about fivefold from
E18 to P4, but rebound by P14, whereas 2-AG levels remained
constant at E18 and P4, but then decreased by about 50% at P14.
Taken together, these results indicate that during muscle for-
mation, both in vitro and in vivo, the endogenous levels of 2-AG
decline with myotube formation and muscle growth, respectively.
CB1 and CB2 Expression Profile During Murine C2C12 and Primary
Human Skeletal Muscle Cell Differentiation. In our attempt to char-
acterize the ECS and its role during skeletal muscle cell differen-
tiation, the expression of transcripts from the Cnr1 and Cnr2 genes,
encoding for CB1 and CB2 receptors, respectively, was also evalu-
ated in C2C12 myoblasts [in growth medium (GM)] and at different
time points (1–3 d) during myotube formation [in differentiation
medium (DM)], by qPCR. The results obtained show that Cnr1
expression was already strong in proliferating myoblasts and further
increased after 1 d of exposure to DM, reaching a plateau after
2 d (Fig. 2A). In contrast, Cnr2 expression in myoblasts (GM) was
much lower, and did not significantly increase after 1 d of exposure
to DM; however, an increase in Cnr2 mRNA levels was found after
2 d of cell exposure to DM, and this continued after 3 d (Fig. 2A).
Likewise, in primary human skeletal muscle cells (hSkMC), we
found that CNR1 mRNA expression was increased by about
eightfold after 2 d of myoblast exposure to DM. In contrast, CNR2
gene expression was not modified (Fig. 2B). In C2C12 cells, in
keeping with the observed Cnr1 and Cnr2 mRNA expression
profile, Western blot analysis showed a >4-fold increase in CB1
receptor expression, with much smaller effects on CB2 (Fig. 2C).
Fig. 1. Changes in AEA and 2-AG levels during C2C12 cell differentiation. (A and D) Endogenous levels of AEA and 2-AG were quantified by LC-APCI-MS in
C2C12 myoblasts at day 0 (GM) and after 3 and 7 d of exposure to DM (A) or mouse quadriceps femoris at E18 and at 4 and 14 d after birth (P4, P14, re-
spectively) (D). AEA and 2-AG levels are normalized to the total lipid amounts extracted from cells. (B) Relative mRNA expression profiles of genes involved in
AEA and 2-AG metabolism during C2C12 differentiation (up to 3 d) by qPCR analysis. (C) Western blot analysis (Left) and quantification (Right) of MyHC, Dagla,
Magl, and α-tubulin protein expression in total lysates from C2C12 myoblasts (GM) or cells exposed to DM for the indicated times. The quantification of the
averaged OD values for the MyHC, Dagla, andMagl bands was normalized to that of α-tubulin. *P ≤ 0.05 vs. the respective values in myoblasts (GM) or vs. the
E18 group. Each data point was obtained from at least four independent determinations for each experimental condition.




















In conclusion, these findings indicate that both Cnr1 and Cnr2
genes are expressed in murine C2C12 cells, with Cnr1 being the
most expressed and more rapidly up-regulated within the first
24–48 h of myotube formation. Down-regulation of Cnr1 was
instead observed in vivo in mice, for example, in the quadriceps
femoris, during development from E18 to P4 (see below).
Effects of AEA, 2-AG, and Noladin Ether on the Early Phase of
Myotube Formation. To clarify the biological significance of the
changes described so far, C2C12 myoblasts were induced to dif-
ferentiate in the presence of exogenous AEA or 2-AG or of drugs
able to selectively modulate EC levels or activity at receptors.
After 1 d of exposure to DM (± drugs), total mRNA was isolated
under each condition and analyzed by qPCR to examine the ex-
pression levels of specific skeletal muscle differentiation-related
genes, such as myogenin (Myog), troponin T1 (Tnnt-1), and Krp1
(Sarcosin), which are normally up-regulated during myotube for-
mation in C2C12 cells (Fig. S1).
As shown in Fig. 3A, exogenous 2-AG (1–3 μM), but not AEA
(1–3 μM), significantly inhibitedMyogmRNA expression. However,
considering that FAAH and MAGL are active also on synthetic
AEA and 2-AG, we evaluated the effects of these exogenous ECs in
the presence of selective DAGLα, FAAH, and MAGL inhibitors,
i.e., OMDM188 (1 μM), URB567 (0.6–1 μM), and JZL184 (0.6–
1 μM), respectively. Inhibiting endogenous 2-AG biosynthesis or
degradation with OMDM188 and JZL184 (1 μM) per se slightly
enhanced and reduced Myog transcript levels, respectively, sug-
gesting the presence of an endogenous tone of 2-AG exerting an
inhibitory effect on myogenesis (Fig. 3B). Indeed, exogenous 2-AG
(3 μM) when provided to C2C12 cells together with a noneffective
dose of JZL184 (0.6 μM) produced a stronger inhibition of Myog
expression (Fig. 3B). By contrast, exogenous AEA (1–3 μM) given
alone or in combination with a noneffective dose of URB567 (0.6
μM) did not alter Myog mRNA expression. URB567 at 1 μM also
produced no effect on Myog mRNA expression (Fig. 3B). More-
over, 2-arachidonylglyceryl ether (noladin ether), a nonhydro-
lyzable structural analog of 2-AG showing high affinity for CB1
(22, 23), inhibited in a more potent and dose-dependent manner
(EC50 = 0.52 μM) the expression of Myog (Fig. 3C) as well as of
Tnnt-1 and Krp1 mRNA (Fig. S2A).
In summary, activation of CB1 receptors with either exogenous
or endogenously elevated (2-AG but not AEA) ECs, or a more
enzymatically stable 2-AG analog, inhibits C2C12 myoblast differ-
entiation, whereas inhibition of 2-AG biosynthesis produces the
opposite effect.
Pharmacological and Genetic Manipulation of CB1 and CB2 Receptors
During C2C12 Cell and Primary hSkMC Differentiation. To clarify the
role played by CB1 and CB2 receptors in myogenesis, we exposed
C2C12 cells to DM for 24–72 h in the presence of selective CB1 or
CB2 agonists or inverse agonists. Arachidonoyl-2-chloroethylamide
(ACEA), a CB1 agonist selective against CB2 receptors (24), sig-
nificantly reduced the mRNA expression levels ofMyog in a dose
(up to 3 μM) and time-dependent manner (up to 3 d of DM
exposure) (Fig. 4 A and B). Also the mRNA expression levels
of Tnnt-1 and Krp1 were reduced after C2C12 cell exposure to
ACEA (1–3 μM) (Fig. S2B).
A decrease inMyogmRNA expression was also found after 24 h
of C2C12 cell exposure to DM in the presence of the CB1/CB2
receptor agonist WIN 55,212–2 (up to 3 μM; EC50 = 0.68 μM)
(Fig. S2C). Interestingly, SR141716 (rimonabant) and AM251,
two selective antagonists/inverse agonists at CB1 receptors (25,
26), enhanced the mRNA expression levels of Myog in a dose-
dependent manner (up to 3 μM; EC50 = ∼0.8 μM for both drugs)
(Fig. 4 C and D) as well as those of Tnnt-1 (Fig. S2C) after 24 h of
exposure. Finally, ACEA effects were counteracted by a non-
effective dose of SR141716 (0.6 μM) (Fig. 4E).
Interestingly, also in hSkMCs, we found that MYOG and
TNNT1 transcript levels were reduced after 2 d of myoblast
Fig. 2. CB1 and CB2 mRNA and protein expression profile during murine
C2C12 and hSkMC myotube formation. (A and B) qPCR analysis of Cnr1 and
Cnr2 mRNA expression levels in C2C12 (A) or hSkMC (B) in GM or exposed to
DM for various amounts of time. Data are expressed as 2-ΔΔCt relative to S16.
*P < 0.05 vs. myoblasts (GM). (C) Western blot analysis of CB1 and CB2
protein levels in differentiating C2C12 cells. Representative blots showing the
approximate molecular mass of each CB protein (expressed in kDa) (Upper)
and quantification of the averaged OD values for CB1 and CB2 normalized
to those of α-tubulin (Lower) are shown. *P ≤ 0.05 vs. respective myoblasts
(GM). Each data point is from at least four independent determinations.
Fig. 3. Effect of AEA, 2-AG, and noladin ether on the early phase of myo-
tube formation in C2C12 cells. (A and B) Myogenin (Myog) mRNA expression
levels were quantified by qPCR after exposure of C2C12 cells to DM for 24 h in
presence of vehicle (DMSO), 2-AG, AEA, OMDM188, JZL184, and/or URB567
at the indicated concentrations. Each bar represents the mean ± SEM of at
least four separate experiments. (C) Concentration-response curve showing
Myog mRNA expression levels in C2C12 cells exposed to DM for 24 h in the
presence of increasing concentrations of noladin ether.
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exposure to DM (2% HS) in the presence of ACEA (1 μM) or
2-AG (Fig. 4F). Conversely, both MYOG and TNNT-1 mRNA
expression was slightly increased in differentiating hSkMCs after
48 h of exposure to DM in the presence of 3 μMAM251 (Fig. 4F).
To further clarify the role played by CB1 during myotube
formation, we transiently overexpressed the CNR1 gene in C2C12
myoblasts, and the day following the transfection we exposed
the cells to DM for 2 d. After this incubation, qPCR analysis
revealed that Myog and Tnnt-1 mRNA levels were reduced by
about 50% in differentiating C2C12 cells overexpressing CB1
compared with control cells transfected with the empty plasmid
(Fig. 4G). As predicted, in C2C12 cells overexpressing CB1, the
inhibitory effect of ACEA (1 μM) on Myog and Tnnt-1 expres-
sion was stronger than that found in nontransfected or control
plasmid-transfected cells (Fig. 4 A and G).
Next, we used also the opposite strategy of inducing post-
transcriptional Cnr1 gene silencing by using siRNA sequences.
These were transfected into the myoblasts, and the day after the
transfection, cells were exposed to DM for 48 h. Under these
conditions, qPCR analysis could not detect any significant
change in Myog and Tnnt-1 expression in siRNA-Cnr1 cells
compared with control cells (transfected with scrambled siRNA
sequences), although Myog expression showed a trend towards
up-regulation (Fig. 4H). Importantly however, in CB1-silenced
cells exposed to DM, the inhibitory effect of ACEA (1 μM) on
Myog and Tnnt-1 expression was completely lost, thus arguing
strongly in favor of a CB1-mediated mechanism.
The selective CB2 receptor agonist JWH-133 (27) also reduced
Myog mRNA expression at the dose of 3 μM. However, this effect
was only partially reversed in the presence of the selective CB2
antagonist/inverse agonist AM630 (28), which per se (1 μM) did not
change Myog mRNA expression (Fig. S3 A and B).
Thus, taking into consideration the Cnr1 and Cnr2 gene expres-
sion profiles and the pharmacological and biochemical evidence
described so far, it appears that the ECS is regulated during myo-
genesis in a way such that CB1 receptor expression and stimulation
exerts an inhibitory effect on the differentiation process in both
murine C2C12 cells and hSkMC.
Morphological Analysis of Myotube Formation During CB1 Stimulation
in C2C12 Cells. Given the above described inhibitory effects of CB1
stimulation on the expression of early markers of myogenesis
(Myog, Tnnt-1), we carried out a morphological analysis to evaluate
the effects of prolonged exposure to 2-AG and ACEA on myotube
Fig. 4. Pharmacological and genetic manipulation of CB1 receptors during
C2C12 cell differentiation. (A–D) Myogenin (Myog) mRNA expression levels,
as evaluated by qPCR, in C2C12 cells exposed to DM for 24 h in the presence
of increasing concentrations of ACEA (up to 3 μM, EC50 0.72 μM) (A), in the
presence of 1 μM of ACEA incubated for the indicated times (B) and in re-
sponse to increasing concentrations of SR141716 (up to 3 μM, EC50 0.82 μM)
(C) or AM251 (up to 3 μM, EC50 0.78 μM) (D). Each data point of the con-
centration-response curves represents the mean ± SEM of three to four
separate determinations performed in quadruplicate. *P ≤ 0.05 vs. the
lowest noneffective concentration (0.1 μM for each drug). (E) After 24 h of
DM exposure, the inhibition effect of 3 μM of ACEA onMyog expression was
prevented by SR141716 at the noneffective concentration of 0.6 μM. (F)
Effect of ACEA (3 μM), 2-AG (3 μM), and AM251 (3 μM) onMYOG and TNNT-1
expression levels in primary hSkMC after 48 h of exposure to DM. *P ≤ 0.05
vs. GM (+ veh); ‡P ≤ 0.05 vs. DM (+veh). (G and H) mRNA expression levels of
Myog and Tnnt-1 in CB1 overexpressing (G) or silenced (H) C2C12 cells ex-
posed to DM for 48 h in control-transfected cells exposed to vehicle (white
columns) and CB1 or CB1 siRNA-transfected cells in the presence of vehicle
(0.1% DMSO, black columns) or ACEA (1 μM, gray columns). *P ≤ 0.05 vs.
control-transfected C2C12 cells. Data are means ± SEM of at least four sep-
arate experiments.
Fig. 5. Morphological analysis of myotube formation after ACEA and 2-AG
exposure in murine C2C12 and human primary satellite cells. (A) Immuno-
fluorescence analysis of C2C12 myoblasts exposed to DM for 4 d in the
presence of vehicle (DMSO, control), 2-AG, or ACEA. MyHC (red) and DAPI
(blue) in myoblasts (a) and in myotubes exposed to DMSO (b), 3 μM of 2-AG
(c), and 3 μM of ACEA (d). (Scale bar, 10 μm.) The percentage of loss of
polynucleated myotubes (fusion index) was calculated in both 2-AG– and
ACEA-treated cells relative to the control-MyHC(+) myotubes (Lower). *P ≤
0.05 vs. control-MyHC(+) cells. (B) Desmin immunofluorescence (green) and
DAPI (blue) signal in control (a) or 2-AG–treated (b) human primary satellite
cells differentiated for 7 d. The fusion index (Lower) was calculated in con-
trol (vehicle) and 2-AG–treated cells relative to control-desmin(+) cells. *P ≤
0.05 vs. desmin(+) cells. Values are from independent fusion index mea-
surements performed in 15 microscopic fields, randomly selected from four
coverslips for each experimental condition (control or drug exposure).




















formation by staining C2C12 cells after 4 d of exposure to DM (±
drugs) with an antibody directed against the MyHC protein. MyHC
is a widely used marker of mature myotube formation (29). DAPI
was also used to stain the nuclei. After 4 d of DM in the presence
of vehicle (DMSO), myoblasts fused to form myotubes (Fig. 5 A,
a and b). By contrast, when the DM contained 2-AG (3 μM) or
ACEA (3 μM), myotube formation was strongly impeded as
revealed by the decreased number and size of MyHC red-positive
myotubes detected (Fig. 5 A, c and d). Quantification of these
pharmacological effects, using the percentage of loss of fused
polynucleated myotubes (fusion index), revealed a significant
impairment in C2C12 myotube formation with 2-AG or ACEA
treatment (Fig. 5A, Lower).
Next, we investigated the 2-AG effect on primary satellite cells
isolated from human muscle specimens from four different donors.
Normally, 6–7 d of DM exposure represents the minimum period
required to begin fusion in primary satellite cells, whereas at
least 1 month is necessary to form mature myotubes (30). To
evaluate the effect of 2-AG on the early phase of satellite cell
differentiation, after 7 d of their exposure to DM, we evaluated
the fusion index by staining the cells with an antibody against
desmin, a canonical skeletal differentiation marker (30), and
DAPI. We found that differentiating human satellite cells trea-
ted with 2-AG (1–10 μM), after 7 d of exposure to DM, exhibit
a significant and dose-dependent decrease of fused, desmin-
positive cells (Fig. 5B).
In an attempt to determine the relevance of CB1 to myo-
genesis in vivo, we examined the gastrocnemius muscles of
Cnr1−/− mice at different developmental time points (Fig. 6).
At E18, the number of MyHC fibrils per muscle fascicle was
increased in Cnr1−/− mouse tissues. At this age, we also observed
a coincident increase in the number of nuclei per primary fascicle
(Fig. 6 A, B, F1, and F2), whereas the cross-sectional area of the
individual fibers remained constant. However, the ratio between
the number of nuclei and the number of muscle fibers per muscle
fascicle (Fig. 6F3) remained unchanged between wild-type and
Cnr1−/− mice. We suggest that these data provide genetic evi-
dence of increased differentiation in topologically disorganized
muscle fascicles with Cnr1 deletion.
By P5, knockout of Cnr1 was associated with a marked in-
crease in MyHC and increased myofibril diameter, although not
in the cross-sectional area (Fig. 6 C and D). Similar to the results
of our analysis at E18, the muscle fiber/nucleus ratio in Cnr1−/−
mice remained unchanged relative to wild-type littermates, sug-
gesting a primary effect of the genetic manipulation on muscle
differentiation rather than on cell proliferation (Fig. 6 G1–G4).
The qPCR analysis of muscle samples at E18 and P5 confirmed
the presence of Cnr1 expression in wild-type controls and its
absence in Cnr1−/− littermates. Cnr2 levels remained unchanged.
Fig. 6. Morphological analysis of skeletal muscle structure in Cnr1−/− mice. (A–B2) Cross-sections of the musculus gastrocnemius pars interna of E18 mouse
embryos. Note that the diameter of individual muscle fibers was unchanged in Cnr1−/− (B–B2) mice relative to wild-type controls (A–A2). However, a striking
difference in the anatomical organization of muscle fibers of Cnr1−/− mice was seen, compared with wild-type controls. (C–D2) Longitudinal sections of the
gastrocnemius pars externa at P5. Note that the diameter of single fibers (d) is increased in Cnr1−/−mice (D–D1), compared with wild-type controls (C–C1). (E)
Schematic representation of the cellular components and organization of muscle fascicles. (F–F3) In E18 embryos, the area of MyHC-positive muscle fibers was
not significantly changed in Cnr1−/− mice, compared with wild-type controls (F). In contrast, a significantly increased number of muscle fibers (F1), as well as
the density of nuclei, was observed (F2). Note that the ratio of number of nuclei per muscle fibers remained unchanged in Cnr1−/− mice relative to wild-type
controls (F3). (G) Plotting of data from >150 muscle fibers/group showed that the surface area of MyHC-positive muscle fiber profiles from cross-sections in
Cnr1−/− mice had a larger spread than in controls, suggesting the deregulation of fiber differentiation. (G1) More detailed analysis of the diameter of
longitudinal muscle fibers (C–D2) revealed significantly increased diameter of individual longitudinal muscles fibers. (G2–G4) In P5 cross-sections (histo-
chemical data not shown), the number of muscle fibers (G2) and nuclei (G3) per fascicle coincidently increased (reaching significance in G3). However, the
ratio of these parameters remained unchanged (G4), suggesting the unlikely contribution of cell proliferation to the Cnr1−/− mice phenotype. Data were
expressed as means ± SEM; *P < 0.05. (Scale bar, 10 μm for A2, B2, C2, and D2). (H) MyHC mRNA expression levels in quadricipes femoris dissected from the
mouse leg at E18 and P5. Each bar represents the mean ± SEM of at least three separate determinations. *P < 0.05 vs. wild type.
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The expression levels of the muscle marker MyHC showed no
difference between wild-type and Cnr1−/− mice, although an in-
creasing trend was observed at P5 in Cnr1−/− mice (Fig. 6H).
Pharmacological, Electrophysiological, and Biochemical Evidence for
a PIP2-Mediated Functional Interaction Between CB1 Receptors and
Kv7 Potassium Channels in C2C12 Cells. Given that ion channels, and
K+ channels in particular, play a critical role in skeletal myogenesis,
and in consideration of the permissive role in this process recently
attributed to Kv7.4 channels (13, 14), we investigated the expres-
sion profile of both Cnr1 and Kv7.4 in vivo during muscle de-
velopment. Toward this aim, we dissected the quadriceps femoris
from mice at E18 and P4 and subjected them to qPCR analysis.
We observed a robust increase in MyHC mRNA expression from
E18 to P4, indicating increased muscle development. By P4, Cnr1
transcript levels were decreased (about 50%) compared with
embryonic expression, whereas, in contrast, muscle Kv7.4 mRNA
expression was increased by about 12-fold (Fig. S4). These data
indicate that in vivo myogenesis is associated with a down-reg-
ulation of CB1 expression and an up-regulation of Kv7.4.
To explore the possible involvement of Kv7.4 channels in the
antimyogenic effects of CB1 activation in C2C12 myoblasts, a
pharmacological approach was first used, in which C2C12 cells were
exposed to DM for 48 h in the absence or presence of the CB1
receptor agonist ACEA and the selective blocker of Kv7 channels
XE991 (31); differentiation was assessed by qPCR quantification of
myogenic marker transcript levels. When differentiating C2C12 cells
were exposed to either ACEA (3 μM) or XE991 (60 μM), the
mRNA expression levels of Myog and Tnnt-1 were similarly re-
duced by about 50% (Fig. S4). When the cells were exposed to
the two drugs together, their effects were not additive (P > 0.05
vs. ACEA 3-μM group), thus arguing in favor of a common
molecular mechanism of action for the two drugs (Fig. S4).
To gain direct evidence of the possible consequences of CB1
receptor activation on Kv7.4-mediated currents, we performed
electrophysiological experiments in CHO cells transiently coex-
pressing both Kv7.4 channels and CB1 receptors. This strategy was
chosen because the Kv7.4 currents could not be recorded in native
C2C12 cells (14). Bath application of ACEA (5 or 10 μM) caused
a concentration-dependent inhibition of Kv7.4 currents (Fig. 7 A
and D). During ACEA perfusion, the addition of the CB1 an-
tagonist SR141716A (SR1; 0.5 μM) abolished the inhibition of
Kv7.4 currents induced by the CB1 agonist (Fig. 7 A and D). In-
hibition of Kv7.4 currents was also observed with the endocanna-
binoid 2-AG (5 μM) (Fig. 7 B and E), as well as with the classical
Kv7 channel blocker XE991. PLC stimulation is a critical trans-
duction mechanism triggered upon CB1 receptor activation in
a variety of cell types (32–34). Treatment with the PLC inhibitor
U73122 (1 μM) fully inhibited ACEA-induced inhibition of Kv7.4
currents [Kv7.4 current inhibition was 36 ± 5% in the presence of
10 μMACEA (n = 11) and 6 ± 3% in the presence of ACEA plus
U73122 (n = 7; P < 0.05)] (Fig. 7 C and F). Fig. 7G shows pop-
ulation data from a large number of cells studied under each ex-
perimental condition described; data are expressed as current
density (pA/pF) relative to controls (DMSO). Altogether, these
results suggest that, in a heterologous expression system, CB1
stimulation triggers PLC-mediated inhibition of Kv7.4 currents.
PIP2 levels are crucial regulators of Kv7 channels activity (19),
and the activation of several receptors (muscarinic, in particular)
is known to suppress Kv7 channel function by depleting mem-
brane PIP2 levels. To test whether CB1 receptor activation also
suppresses Kv7.4 currents by a PLC-dependent decrease in PIP2
levels, the endogenous levels of this phospholipid were measured
by ELISA in C2C12 myoblasts after 24 h of exposure to ACEA (1–
3 μM). In this experiment, we decided to use undifferentiated cells
to avoid the potentially confounding effects due to ACEA-induced
inhibition of cell differentiation. As shown in Fig. 8A, ACEA
significantly decreased PIP2 levels by about 30–40% in C2C12
myoblasts. The effect of ACEA (1–3 μM) on PIP2 levels was also
evaluated by measuring the signal intensity of the green fluores-
cent Bodipy-FL PIP2. In these experiments, the Bodipy-FL-PIP2
was first conjugated with the Shuttle PIP carrier and then added to
the cells in serum-free medium for 10–15 min to allow its in-
corporation into the cell (seeMaterials and Methods). As shown in
Fig. 8B, in myoblasts exposed to the vehicle (DMSO), Bodipy-
FL-PIP2 produces a strong green fluorescent signal, which was
markedly reduced following 5–10 min of ACEA (1–3 μM) expo-
sure. The effect of ACEA was quantified by measuring the fluo-
rescence intensity signal in randomly selected cell groups under
each experimental condition (Fig. 8B, Lower). Finally, to gain
conclusive evidence of a CB1-sensitive association between PIP2
and Kv7 channels, we exposed C2C12 myoblasts for 24 h to ACEA
or vehicle and then assayed Kv7.4 coimmunoprecipitated PIP2
levels. ACEA (1 and 3 μM) caused a robust reduction of
coimmunoprecipitated PIP2, whereas Kv7.4 expression was
unchanged (Fig. 8C). Carbachol (10 μM), a canonical agonist of
Gq-coupled muscarinic receptors used as a positive control,
caused a similar effect. In conclusion, these findings clearly
support the idea that the inhibitory effect of CB1 receptor ac-
tivation on myogenesis is largely dependent on the inhibition of
Kv7.4 activity through Gq/PLC-mediated PIP2 hydrolysis.
Effect of 2-AG and ACEA on C2C12 Myoblast Proliferation. Finally, to
show that the increased number of fibers and nuclei per fascicle
observed in the muscle of Cnr1−/− mice was not due to a negative
effect of CB1 tone on myoblast proliferation, as suggested by the
fact that the ratio between nuclei and muscle fiber was not al-
tered in these mice, we investigated the effect of CB1 activation
Fig. 7. CB1 receptor stimulation inhibits Kv7.4-mediated currents in CHO
transfected cells. (A) Representative trace showing how ACEA in a concen-
tration-dependent manner inhibits Kv7.4 currents. ACEA effect on Kv7.4
currents is prevented in the presence of (A) SR1 (0.5 μM) or (C) U73122
(1 μM). (B) Effect of 2-AG (5 μM). (D) Time course of the effects of ACEA (5 μM,
white circles; 10 μM, light-gray circles) on Kv7.4 currents in CHO cells coex-
pressing CB1 receptors in the absence (dark-gray circle) or presence of 0.5 μM
SR1 (white circle and light-gray circles). (F) Time course of the effects of
ACEA (10 μM) on Kv7.4 currents in CHO cells coexpressing CB1 receptors in the
absence or presence of 1 μM U73122. (E) Time course of the effects of 5 μM
2-AG on Kv7.4 currents in CHO cells coexpressing CB1 receptors. (G) Quantifi-
cation of the experiments performed in this study. The length of the bars on
top of the graphs indicate the duration of drug exposure. Asterisks denote
values significantly different (P < 0.05) from the corresponding controls.




















on myoblast proliferation in vitro. To this end, we plated and
synchronized the myoblast cell cycle by exposing C2C12 cells for
18–24 h to DM with low serum and then switching them to GM
supplemented with [3H]thymidine in the absence or presence of
drugs for a further 24 h to measure the effects on proliferation
rate. As shown in Fig. 9, 2-AG (1 μM) and ACEA (1–3 μM)
increased myoblast proliferation by about 30–40%. This pro-
proliferative effect was counteracted by SR141716 (0.6 μM). By
contrast, when myoblasts were exposed to a higher concentration
of SR141716 (1 μM), proliferation was reduced (Fig. 9).
We next evaluated if the proproliferative effect of ACEA was
still present when the compound was given to cells in combina-
tion with pertussis toxin (PTX) or D609, selective blockers of Gi/o
and PLC, respectively (35, 36). Interestingly, D609 (40 μM), but
not PTX (500 ng/mL), significantly counteracted ACEA-
induced proliferation of C2C12 cells, thus suggesting that the
proproliferative effect observed upon CB1 stimulation, like
the differentiation-restricting effect described above, might be
due to a Gq/PLC-mediated mechanism. D609 as well as PTX,
when given alone, did not affect myoblast proliferation (Fig. 9).
[3H]Thymidine incorporation was lowest in those cells where the
DM, after the cell cycle synchronization time, was not replaced
with fresh GM (Fig. 9). In conclusion, CB1 receptor stimulation
increases the number of precursor myoblasts in vitro in a PLC-
dependent manner.
Discussion
EC Signaling Is Altered During Myogenesis in Vitro and in Vivo.
During the early phases of skeletal muscle formation myoblasts
withdraw from the cell cycle and fuse to form large and multinu-
cleated myotubes, which represent the functional contractile unit in
the mature myofiber (8). During this transition the coordinated
action of a large number of genes including those encoding for
transcriptional factors, metabolic enzymes, ion channels, and re-
ceptors, is required. In this study, we described, to our knowledge
for the first time, that the ECS, which plays an important role in
many physiological and pathological aspects of mammalian bi-
ology, participates also in myogenesis. To define the potential
functional role played by the ECS during the early phases of
skeletal muscle formation, we used murine C2C12 cells as a model
of myogenesis in vitro. AEA and 2-AG levels were measured
during the myoblast–myotube transition, and a transcriptomic
analysis of genes known to regulate EC metabolism and activity
was performed. Our data show that 2-AG, but not AEA, levels
significantly decline during C2C12 myotube formation in vitro and
during muscle formation in vivo. In myoblasts this might be due to
an increase in MAGL expression and subsequent increased 2-AG
enzymatic hydrolysis. During myoblast differentiation, we also
found significant increases in the expression of both CB1 and
CB2 receptors, with CB1 showing the strongest degree of up-
regulation within the first 24–48 h of differentiation. Interestingly,
the early phase of human primary myoblast differentiation was
accompanied by CB1, but not CB2, up-regulation. Importantly,
sufficient expression of CB1 mRNA and protein seems to occur
also in both murine and human myoblasts, thus allowing for a
possible modulation by the ECS of the early steps of myogenesis
and suggesting pharmacological experiments in this direction.
Functional Role of the ECS During Skeletal Muscle Proliferation and
Differentiation. We next investigated the possible function of the
observed changes in EC levels and of CB1 and CB2 gene ex-
pression by pharmacological and biochemical approaches. To in-
crease the levels of both AEA and 2-AG during the early phase of
C2C12 cell differentiation and study the potential effects on myo-
genesis, we used both exogenous EC and selective inhibitors of
Fig. 8. CB1 stimulation by ACEA reduces endogenous PIP2 levels and BODY-
PY PIP2 fluorescence and PIP2 binding to Kv7.4 K
+ channels in C2C12 myo-
blasts. (A) Endogenous levels of PIP2 quantified by ELISA in control (DMSO)
and treated cells after 24 h of exposure to ACEA (1 and 3 μM) in GM. Each
bar represents the mean ± SEM of three to four separate determinations
performed in quadruplicate. *P < 0.05 vs. control (no drug added). (B) C2C12
myoblasts incubated with BODY-PY PIP2 showing a green fluorescent signal
in the control (DMSO) condition (a) and a robust decrease of signal after
5–10 min of exposure to 1 μM (b) or 3 μM (c) of ACEA. (Lower) The total
signal intensity obtained arbitrarily by choosing four to six distinct prep-
arations of cells. (C, i ) The PIP2 signal in the immunoprecipitated samples
for Kv7.4 (IP:Kv7.4) following the treatment with ACEA (1–3 μM) or car-
bachol (10 μM) by the use of a specific antibody (Materials and Methods).
(ii ) The Kv7.4 protein signal intensity on the same samples and mem-
branes. (iii and iiii ) The Kv7.4 and α-tubulin protein expression in the
flow-through sample under each condition. The graph bar indicates the
PIP2 band intensity value normalized to the relative amount of Kv7.4 in
each condition.
Fig. 9. Effect of 2-AG and ACEA on C2C12 cell proliferation. C2C12 myoblasts
were synchronized by exposure to DM for 18–20 h; after this period, cell
proliferation was assessed by [3H]thymidine incorporation into cells grown
for a further 24 h in GM (with or without the indicated drugs). Each point
represents the mean ± SEM of three to four separate determinations per-
formed in quadruplicate. *P < 0.05 vs. GM controls (no drug added). DM
served as control condition as it represents the group of cells in which the
DM was not refreshed with the GM after the starvation time of 18–20 h.
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FAAH and MAGL. We found that 2-AG, but not AEA, inhibits
myotube formation. A similar effect was found following exposure
of differentiating C2C12 cells to the selective synthetic CB1 agonist
ACEA, which markedly reduced the expression of skeletal muscle
differentiation markers (Myog and Tnnt-1) in a dose- and time-
dependent manner and in a way antagonized by per se inactive
doses of two selective CB1 blockers. These latter compounds, when
given to cells at higher doses, as well as an inhibitor of 2-AG bio-
synthesis, instead increased Myog and Tnnt-1 expression. These
data, together with the above finding that endogenous 2-AG is
produced in higher amounts in myoblasts and that an inhibitor of
2-AG degradation also counteracted myogenesis, suggest that
this EC exerts a tonic negative control on myogenesis by acti-
vating CB1 receptors and that such control is released to allow
myogenesis by increasing the expression of the 2-AG–inactivat-
ing enzyme. On the other hand, the up-regulation of CB1 ex-
pression immediately after the start of differentiation can be
seen as a potential way of compensating for the decreased levels
of 2-AG and allowing for a negative feedback control of myo-
genesis. This hypothesis is supported by our observation that
overexpression of CB1 inhibited C2C12 cell differentiation and
heightened the inhibitory effect of ACEA, which instead was
abolished by CB1 receptor knockdown. On the other hand,
experiments with pharmacological tools selective for CB2, to-
gether with the much lower up-regulation of the latter during
myogenesis, seem to rule out an important effect for this 2-AG
target in myotube formation. Importantly, CB1 negative con-
trol of differentiation was observed also when using primary
human myoblasts. Furthermore, when differentiation was carried
out starting from human satellite skeletal muscle cells from healthy
donors, 2-AG was again capable of inhibiting differentiation.
Finally, immunohistochemical and morphological analyses of
skeletal muscle from CB1 null mice at E18 and P5, confirmed that
CB1 receptors clearly play a role in inhibiting myotube differenti-
ation and muscle formation also in vivo. In fact, during muscle
development, both the number of fibers and nuclei in each fascicle
were increased in the absence of CB1. Two lines of evidence in-
dicate that this morphological observation can be explained with
stimulation of myoblast differentiation rather proliferation by CB1
knockout. First, the ratio between nuclei and fibers in CB1 null
mice at both E18 and P5 remained constant. Second, and most
importantly, we found that, in vitro, CB1 antagonism, rather than
enhancing, in fact reduces (whereas CB1 agonism enhances) C2C12
myoblast proliferation, an effect that might be a mere consequence
of the effect on differentiation shown here, as observed for CB1 in
many cell types including neuronal stem cells, adipocytes, osteo-
blasts, smooth-muscle cells, etc. (37–39), and not necessarily oc-
curring in vivo. Thus, it is likely that the observed increase in fiber
number in CB1 null mice is due to the absence of 2-AG/CB1
negative control over satellite cell differentiation into myoblasts
(Fig. 5B) and over myoblast differentiation into myotubes (Fig. 4),
rather than to the absence of a negative control on myoblast pro-
liferation. Such effects would be sufficient to sustain an increased
muscle formation even in the absence of direct effects on myoblast
proliferation.
In C2C12 Cells, CB1 Stimulation Causes PIP2 Hydrolysis. We next in-
vestigated the molecular mechanism(s) through which CB1
controls myoblast proliferation and differentiation. CB1 belongs
to the metabotropic class of receptors and, although prevalently
coupled to Gi/o proteins, it can also trigger Gq/11 activation and
subsequent PLC activation (32–34, 40). Indeed, we provided
evidence that, in C2C12 cells, ACEA reduces the endogenous
levels of the PLC substrate, PIP2. We surmise that, in differen-
tiating myoblasts, CB1 activation leads to the activation of PLC
and the subsequent hydrolysis of PIP2. Accordingly, we showed
that the proproliferative effect produced by ACEA on C2C12
myoblasts is abolished by a PLC inhibitor, but not by PTX. CB1-
induced PIP2 hydrolysis might also release channels involved in
differentiation from the positive control that PIP2 usually exerts
thereupon and, at the same time, lead to the formation of
diacylglycerols and IP3, with subsequent activation of protein
kinase C and intracellular calcium mobilization, all of which have
been implicated in both cell differentiation and proliferation (41, 42).
CB1 Receptor Activation-Induced PIP2 Hydrolysis Leads to Reduced
Function of Kv7 Potassium Channels. Kv7 represents a subclass of
K+ channels comprised of five distinct members (Kv7.1– Kv7.5),
each showing distinct subcellular localization, biophysical proper-
ties, modulation, and pharmacological profile (43). Kv7.1 subunits,
together with the auxiliary subunits KCNE1, form the molecular
basis of delayed rectifier K+ currents, which control action poten-
tial repolarization in cardiomyocytes, whereas Kv7.2, Kv7.3, Kv7.4,
and Kv7.5 give rise to K
+ currents (such as the M current) widely
distributed in neuronal and primary sensory cells and acting as
primary regulators of the intrinsic electrical properties of excitable
cells (44). To date, the spectrum of functions attributed to Kv7
subunits has been enlarged following their description in smooth
muscle cells of vascular and visceral tissues and in skeletal muscle
cells. In this context, we recently showed that significant changes in
the expression levels of some members of the Kv7 subclass of
voltage-gated K+ channels, most notably Kv7.4, accompany the
myoblast-to-myotube transition in murine C2C12 cells (14).
Over the past decade, many studies have described how the
decrease of membrane PIP2 concentrations represents one of
the main molecular mechanisms by which Gq/11-coupled metabo-
tropic receptors inhibit the activity of Kv7 channels. Moreover,
Kv7 channel open state probability also depends on its intrinsic
affinity for intracellular PIP2 (45), with higher PIP2 concen-
trations increasing the open state probability of Kv7 channels. In
view of the present data showing that CB1 stimulation in C2C12
cells reduces differentiation and stimulates proliferation—i.e., two
effects that are opposite to those observed following activation of
Kv7 channels (13)—we hypothesized that CB1 receptor stimula-
tion, by reducing PIP2 levels, might indirectly inhibit Kv7 channels.
By using selective pharmacological tools and biochemical and
electrophysiological approaches, we have provided strong evi-
dence in favor of this hypothesis. In fact, we showed that CB1
stimulation reduces (i) the Kv7.4-mediated K
+ current in a PLC-
dependent manner in CHO cells heterologously expressing CB1
and Kv7.4, but not in cells expressing only Kv7.4, and (ii) the
amounts of PIP2 associated with Kv7.4 channels. We also in-
vestigated the potential effect of CB1 stimulation by ACEA on the
IP3-dependent intracellular Ca2+mobilization, an event also known
to be coupled to inhibition and stimulation of myoblast differenti-
ation and proliferation, respectively (46). However, in FURA-2:00
AM-labeled C2C12 myoblasts exposed to DM for 24 h in a Ca
2+-free
buffer, we could observe only a slight increase of [Ca2+]i in response
to ACEA. Interestingly, the M1 muscarinic receptor (but not the B2
bradykinin receptor) also was reported to inhibit Kv7 in the brain in
a manner similar to that observed here in myoblasts for CB1—i.e.,
by decreasing PIP2 binding to the channel, rather than by increasing
[Ca2+]i and leading to calmodulin activation (15). The role of
diacylglycerol and protein kinase C in CB1-mediated inhibition of
Kv7.4 might therefore be an interesting subject of investigation for
future studies in myoblasts.
Conclusions. The present study suggests that 2-AG, via CB1 ac-
tivation, plays a crucial role in the control of myotube formation,
and highlights Kv7.4 potassium channels as one important down-
stream target for this function. The novel molecular mechanism
described here could open new avenues for the development of
endocannabinoid-based therapies against skeletal muscle diseases
characterized by abnormal repair and differentiation.





















Cell Culture and Drugs. C2C12 myoblasts were cultured and differentiated as
previously described (13) (SI Materials and Methods). Satellite cells were
obtained from muscle tissue from orthopedic surgery, as approved by the
Ethical Committee of the University Medical School of Debrecen, and dif-
ferentiated as previously described (30) (SI Materials and Methods).
Measurement of Endocannabinoids AEA and 2-AG. The extraction, purification,
and quantification of EC from tissues was performed as previously described
(47) (SI Materials and Methods).
Cell Transfection and Cnr1 Gene Silencing and/or Overexpression. Myoblasts
were plated in six-well culture dishes, and the next day, 4 μg of total DNA of
pcDNA3.1-CNR1, or empty vector and a plasmid encoding for the enhanced
green fluorescent protein (Clontech), was transfected using Lipofectamine
LTX (Life Technologies) according to the manufacturer’s instructions. The
following day, C2C12 myoblasts were exposed to DM for 48 h in the presence
or absence of ACEA before RNA isolation and quantitation. Cnr1 silencing
was obtained by transfection of myoblasts plated in six-well culture dishes
with endoribonuclease-prepared siRNA sequences (EMU088771 Sigma-Aldrich)
using Lipofectamine RNAimax (Life Tecnology). The following day, the cells
were exposed to DM for 48 h in the presence or absence of ACEA before RNA
isolation and quantitation.
RNA Extraction and qPCR. Total RNA isolation, purification, and cDNA syn-
thesis were performed as described (13) (SI Materials and Methods).
Cell Proliferation Assay. C2C12 cell proliferation was assessed as previously
described (13).
Western Blots. C2C12 cells were subjected to Western blot analysis as de-
scribed previously (13). For this study we used the following antibodies:
mouse anti-myosin heavy chain antibody, clone A4.1025 (1:1,000; Millipore);
mouse anti-CNR1 (1:500; catalog no. Y080037, Applied Biological Materials
Inc.); mouse anti-CNR2 (1:400; Sigma-Aldrich); mouse anti-MGL clone N90/20
(1:4; Antibodies Inc.); and goat anti-DAGLα lot (1:1,000; Abnova). An anti–
α-tubulin antibody (1:5,000; Sigma-Aldrich) was used to check for equal
protein loading. Reactive bands were detected by chemiluminescence (ECL
or ECL-plus; Bio-Rad). Images were analyzed on a ChemiDoc station with
Quantity-one software (Bio-Rad).
Cell or Tissue Morphological Analysis. Murine C2C12 cells were stained as
previously described (14). Primary human muscle cells were stained as pre-
viously described (30). Heterozygous crosses of CB1RKO [n = 3 (E18), n = 2
(P5)] and wild-type littermates [n = 3 (E18), n = 2 (P5)] on C57Bl5/N back-
ground were processed simultaneously. In brief, embryos were harvested
on E18, and the right hind paw was isolated and immersion-fixed for 48 h.
Pups were decapitated on postnatal day 5 with the right hind paw pro-
cessed as above. Subsequently, tissues were cryoprotected in 30% (wt/vol)
sucrose in physiological saline and sectioned at a thickness of 14 μm on
a cryostat microtome (Leica). The cutting plane was perpendicular to the
musculus gastrocnemius pars externa (Fig. 6 A and B) and, consequently,
parallel to the musculus gastrocnemius pars interna (Fig. 6 C and D). Serial
sections were collected on fluorescence-free SuperFrost+ glass slides, air-
dried, and processed for multiple labeling histochemistry according to
standard protocols (48) using a mouse anti-heavy chain myelin antibody
(1:500, Millipore) antibody, Alexa560-conjugated phalloidin to reveal fila-
mentous actin, and Hoechst 33,342 as nuclear dye. Imaging was performed
on a Zeiss780 laser-scanning microscope using spectral detection for the
optimal separation of fluorescence signals. Quantitative morphometry in-
cluded (i) measurement of the cross-sectional surface of individual muscle
fibers (μm2) (Fig. 6 A, B, F, and G), determining (ii) the number of muscle
fibers (Fig. 6 F1–G2) and the number of nuclei (Fig. 6 F2–G3) within primary
muscle fascicles at both ages. Moreover, we measured the cross-sectional
diameter (Fig. 6G1) of muscle fibers on P5. Data were expressed as means ±
SEM; *P < 0.05.
ELISA and BODY-PY PIP2. The amount of PIP2 extracted from C2C12 cells was
measured by using the PIP2 Mass ELISA kit following the manufacturer’s
instructions (Echelon Biosciences Inc.). PIP2 was extracted from control or
ACEA-treated cells (1–3 μM) after 24 h of drug exposure in GM. Cellular PIP2
quantities were estimated by comparing the values from the standard curve,
which showed a linear relationship at the range from 0.5 to 1,000 pM con-
centration. Data were analyzed and graphed by using Graph-prism 5 software.
The BODY-PY green fluorescent PIP2 (catalog no. C-45F6) as well as the shuttle
carrier (catalog no. P-9045) were purchased from Echelon Biosciences Inc.
Immunoprecipitation. C2C12 myoblasts were plated on 100-mm-diameter
petri dishes and exposed to GM in the presence of vehicle (DMSO) or ACEA
(1–3 μM) and carbachol (10 μM) for 24 h. After this time, the cells were
washed twice in PBS (without Mg2+ and Ca2+) and lysed in a buffer solution
(Tris·HCl 50 mM, NaCl 150 mM, 1% Triton X-100, EDTA 2 mM, EGTA 5 mM,
and protease inhibitors mixture). Total lysates were collected and main-
tained under agitation for 30 min at 4 °C before centrifugation for 15 min at
15,000 × g. Supernatants were recovered and quantified by a Bio-Rad DC
Protein Assay Kit. Subsequently, 0.8–1 mg of each lysate sample was used for
the immunoprecipitation (IP) procedure using a Dynabeads Protein G Kit
(catalog no. 10007D; Life Technology) following the manufacturer’s
instructions. Mouse anti-Kv7.4 (IgG1) (catalog no. 75–082, Antibodies Inc.)
was used to immunoprepitate Kv7.4 channels. IP samples were recovered
after heating at 100 °C for 10 min in β-mercaptoetanol sample buffer (2×)
and loaded on precast polyacrylamide gels (4–12% gradient; Bolt Bis-Tris
Plus gels; Life Technologies) and then transferred to a PVDF membrane.
Mouse anti-PIP2 antibody (1:1,000; catalog no. sc-53412, Santa Cruz Bio-
technology) was incubated overnight at 4 °C. All of the proteins not pulled
down by the anti-Kv7.4 antibody/beads complex (flow-through) were loaded
(at a concentration of 50 μg) on precast polyacrylamide gels mentioned
before and blotted using anti-Kv7.4 and anti–α-tubulin (1:500; Sigma-Aldrich)
antibodies to verify the IP procedure.
Whole-Cell Electrophysiology. Currents from transiently transfected CHO cells
(1 d posttransfection) were recorded at room temperature by whole-cell
patch-clamp using an Axopatch 200A amplifier (Molecular Devices) with glass
micropipettes of 3–5 MΩ resistance. The extracellular solution contained (in
mM): 138 NaCl, 2 CaCl2, 5.4 KCl, 1 MgCl2, 10 glucose, and 10 Hepes (pH 7.4)
with NaOH. The pipette (intracellular) solution contained (in mM): 140 KCl,
2 MgCl2, 10 EGTA, 10 Hepes, 5 Mg-ATP (pH 7.4) with KOH. The pCLAMP
software (version 10.2; Molecular Devices) was used for data acquisition and
analysis. Linear cell capacitance (C) was determined by integrating the area
under the whole-cell capacity transient, evoked by short (5–10 ms) pulses
from −80 to −75 mV with the whole-cell capacitance compensation circuit of
the Axopatch 200A turned off. Current densities (expressed in pA/pF) were
calculated as peak of the agonist-evoked currents divided by C. From a
holding potential of −80 mV, currents were activated by 4-s square pulses
from −100 to +40 mV in 20 mV increments, followed by a 4-s isopotential
pulse to 0 mV, or by using voltage ramps in which the membrane voltage
was changed from −100 to +40 mV in 3 s.
Data Analysis. Data are expressed as means ± SEM of the given number of
experiments (n). Data sets were compared by use of unpaired Student t
tests or, if necessary, with one-way analysis of variance, followed by the
Bonferroni’s test using GraphPad Prism 5 software. Statistically significant
differences were accepted when the P value was at least <0.05. The dose–
response curves were calculated using GraphPad Prism 5 software.
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